[
  {
    "ts": null,
    "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
    "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
    "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768325700,
      "headline": "ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon",
      "id": 138087373,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.",
      "url": "https://finnhub.io/api/news?id=e0f59a733f7b0042c09c23bb836a391779a36876afcc394917e5fbad77f50f3d"
    }
  },
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock",
    "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=c21fb25e8d06d3a7e810199c3c7d8093266902079b4e39c41d5631d3d080eb2a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768312803,
      "headline": "Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock",
      "id": 138086836,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=c21fb25e8d06d3a7e810199c3c7d8093266902079b4e39c41d5631d3d080eb2a"
    }
  },
  {
    "ts": null,
    "headline": "Oramed and Lifeward Announce Strategic Transaction",
    "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (\"Oramed\") and Lifeward Ltd. (NASDAQ: LFWD) (\"Lifeward\") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed's proprietary Protein Oral Drug POD™ delivery technology and Oramed obtaining 49.9% beneficial ownership interest in Lifeward upon the satisfaction of certain terms and conditions. In addit",
    "url": "https://finnhub.io/api/news?id=e18e03f686190edd3707370d46559505ee98af9b8091de6eef6fddcd7e10dc1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768309080,
      "headline": "Oramed and Lifeward Announce Strategic Transaction",
      "id": 138083466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (\"Oramed\") and Lifeward Ltd. (NASDAQ: LFWD) (\"Lifeward\") today announced the signing of binding agreements for a strategic transaction between Oramed, Lifeward and a certain accredited investor. The transaction includes the transfer to Lifeward of Oramed's proprietary Protein Oral Drug POD™ delivery technology and Oramed obtaining 49.9% beneficial ownership interest in Lifeward upon the satisfaction of certain terms and conditions. In addit",
      "url": "https://finnhub.io/api/news?id=e18e03f686190edd3707370d46559505ee98af9b8091de6eef6fddcd7e10dc1e"
    }
  },
  {
    "ts": null,
    "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
    "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
    "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768308508,
      "headline": "Tempus AI (TEM) Soars 15% on $1.1-Billion Deal",
      "id": 138083148,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]",
      "url": "https://finnhub.io/api/news?id=61ced03819d123ffc8f14f81ba7966cc2bbf9d87fe288f30c95e6fc3e0d47295"
    }
  },
  {
    "ts": null,
    "headline": "JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff",
    "summary": "BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.",
    "url": "https://finnhub.io/api/news?id=6fedb4532df102f40eb26d6eb1ef86934288f19c7652d3dd6f92245fe74fa62e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768304044,
      "headline": "JPM26: BMS places confidence in core pipeline to weather 2030 patent cliff",
      "id": 138083476,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.",
      "url": "https://finnhub.io/api/news?id=6fedb4532df102f40eb26d6eb1ef86934288f19c7652d3dd6f92245fe74fa62e"
    }
  },
  {
    "ts": null,
    "headline": "SCHD: Market Rotation Beneficiary, Dividend And Capital Appreciation Story Still Compelling",
    "summary": "SCHD dividend ETF remains a Buy: diversified exposure, higher yield & 9.1% 5Y dividend growth, with value holdings like BMY/VZ.",
    "url": "https://finnhub.io/api/news?id=504c31cdd2b48a282e9d7ddb54920e8086a3acdc534dfba6fd9ed76630aeea0f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768303839,
      "headline": "SCHD: Market Rotation Beneficiary, Dividend And Capital Appreciation Story Still Compelling",
      "id": 138085274,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132050/image_1359132050.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "SCHD dividend ETF remains a Buy: diversified exposure, higher yield & 9.1% 5Y dividend growth, with value holdings like BMY/VZ.",
      "url": "https://finnhub.io/api/news?id=504c31cdd2b48a282e9d7ddb54920e8086a3acdc534dfba6fd9ed76630aeea0f"
    }
  }
]